| Interaction type,Description,Subject,DDI type | |
| 67,#Drug1 can cause a decrease in the absorption of #Drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.,2,DDI type 1 | |
| 18,#Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.,1,DDI type 2 | |
| 13,The absorption of #Drug2 can be decreased when combined with #Drug1.,1,DDI type 3 | |
| 3,The bioavailability of #Drug2 can be decreased when combined with #Drug1.,1,DDI type 4 | |
| 62,The bioavailability of #Drug2 can be increased when combined with #Drug1.,1,DDI type 5 | |
| 47,The metabolism of #Drug2 can be decreased when combined with #Drug1.,2,DDI type 6 | |
| 4,The metabolism of #Drug2 can be increased when combined with #Drug1.,1,DDI type 7 | |
| 43,The protein binding of #Drug2 can be decreased when combined with #Drug1.,2,DDI type 8 | |
| 75,The serum concentration of #Drug2 can be decreased when it is combined with #Drug1.,1,DDI type 9 | |
| 73,The serum concentration of #Drug2 can be increased when it is combined with #Drug1.,2,DDI type 10 | |
| 77,The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.,1,DDI type 11 | |
| 11,The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy.,1,DDI type 12 | |
| 70,The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.,1,DDI type 13 | |
| 8,The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1.,1,DDI type 14 | |
| 72,#Drug1 may decrease the excretion rate of #Drug2 which could result in a higher serum level.,2,DDI type 15 | |
| 65,#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.,2,DDI type 16 | |
| 58,#Drug1 may decrease the cardiotoxic activities of #Drug2.,2,DDI type 17 | |
| 15,#Drug1 may increase the cardiotoxic activities of #Drug2.,1,DDI type 18 | |
| 44,#Drug1 may increase the central neurotoxic activities of #Drug2.,1,DDI type 19 | |
| 80,#Drug1 may increase the hepatotoxic activities of #Drug2.,2,DDI type 20 | |
| 57,#Drug1 may increase the nephrotoxic activities of #Drug2.,2,DDI type 21 | |
| 35,#Drug1 may increase the neurotoxic activities of #Drug2.,1,DDI type 22 | |
| 7,#Drug1 may increase the ototoxic activities of #Drug2.,2,DDI type 23 | |
| 45,#Drug1 may decrease effectiveness of #Drug2 as a diagnostic agent.,2,DDI type 24 | |
| 86,The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.,2,DDI type 25 | |
| 49,The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.,3,DDI type 26 | |
| 66,The risk or severity of bleeding can be increased when #Drug1 is combined with #Drug2.,3,DDI type 27 | |
| 50,The risk or severity of heart failure can be increased when #Drug2 is combined with #Drug1.,3,DDI type 28 | |
| 42,The risk or severity of hyperkalemia can be increased when #Drug1 is combined with #Drug2.,3,DDI type 29 | |
| 31,The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.,3,DDI type 30 | |
| 56,The risk or severity of hypotension can be increased when #Drug1 is combined with #Drug2.,3,DDI type 31 | |
| 33,The risk or severity of QTc prolongation can be increased when #Drug1 is combined with #Drug2.,3,DDI type 32 | |
| 52,#Drug1 may decrease the analgesic activities of #Drug2.,2,DDI type 33 | |
| 12,#Drug1 may decrease the anticoagulant activities of #Drug2.,2,DDI type 34 | |
| 37,#Drug1 may decrease the antihypertensive activities of #Drug2.,2,DDI type 35 | |
| 26,#Drug1 may decrease the antiplatelet activities of #Drug2.,1,DDI type 36 | |
| 14,#Drug1 may decrease the bronchodilatory activities of #Drug2.,1,DDI type 37 | |
| 29,#Drug1 may decrease the diuretic activities of #Drug2.,1,DDI type 38 | |
| 17,#Drug1 may decrease the neuromuscular blocking activities of #Drug2.,1,DDI type 39 | |
| 76,#Drug1 may decrease the sedative activities of #Drug2.,1,DDI type 40 | |
| 61,#Drug1 may decrease the stimulatory activities of #Drug2.,2,DDI type 41 | |
| 5,#Drug1 may decrease the vasoconstricting activities of #Drug2.,1,DDI type 42 | |
| 22,#Drug1 may increase the adverse neuromuscular activities of #Drug2.,2,DDI type 43 | |
| 69,#Drug1 may increase the analgesic activities of #Drug2.,2,DDI type 44 | |
| 2,#Drug1 may increase the anticholinergic activities of #Drug2.,2,DDI type 45 | |
| 6,#Drug1 may increase the anticoagulant activities of #Drug2.,2,DDI type 46 | |
| 10,#Drug1 may increase the antihypertensive activities of #Drug2.,1,DDI type 47 | |
| 53,#Drug1 may increase the antiplatelet activities of #Drug2.,2,DDI type 48 | |
| 36,#Drug1 may increase the antipsychotic activities of #Drug2.,2,DDI type 49 | |
| 82,#Drug1 may increase the arrhythmogenic activities of #Drug2.,2,DDI type 50 | |
| 25,#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2.,1,DDI type 51 | |
| 54,#Drug1 may increase the bradycardic activities of #Drug2.,1,DDI type 52 | |
| 46,#Drug1 may increase the bronchoconstrictory activities of #Drug2.,1,DDI type 53 | |
| 16,#Drug1 may increase the central nervous system depressant (CNS depressant) activities of #Drug2.,2,DDI type 54 | |
| 79,#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2.,1,DDI type 55 | |
| 39,#Drug1 may increase the constipating activities of #Drug2.,1,DDI type 56 | |
| 28,#Drug1 may increase the dermatologic adverse activities of #Drug2.,2,DDI type 57 | |
| 74,#Drug1 may increase the fluid retaining activities of #Drug2.,1,DDI type 58 | |
| 51,#Drug1 may increase the hypercalcemic activities of #Drug2.,2,DDI type 59 | |
| 78,#Drug1 may increase the hyperglycemic activities of #Drug2.,2,DDI type 60 | |
| 68,#Drug1 may increase the hyperkalemic activities of #Drug2.,2,DDI type 61 | |
| 71,#Drug1 may increase the hypertensive activities of #Drug2.,2,DDI type 62 | |
| 24,#Drug1 may increase the hypocalcemic activities of #Drug2.,2,DDI type 63 | |
| 9,#Drug1 may increase the hypoglycemic activities of #Drug2.,2,DDI type 64 | |
| 83,#Drug1 may increase the hypokalemic activities of #Drug2.,1,DDI type 65 | |
| 55,#Drug1 may increase the hyponatremic activities of #Drug2.,2,DDI type 66 | |
| 60,#Drug1 may increase the hypotensive activities of #Drug2.,1,DDI type 67 | |
| 41,#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.,1,DDI type 68 | |
| 34,#Drug1 may increase the immunosuppressive activities of #Drug2.,1,DDI type 69 | |
| 63,#Drug1 may increase the myelosuppressive activities of #Drug2.,2,DDI type 70 | |
| 48,#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.,2,DDI type 71 | |
| 27,#Drug1 may increase the neuroexcitatory activities of #Drug2.,1,DDI type 72 | |
| 21,#Drug1 may increase the neuromuscular blocking activities of #Drug2.,2,DDI type 73 | |
| 30,#Drug1 may increase the orthostatic hypotensive activities of #Drug2.,1,DDI type 74 | |
| 1,#Drug1 may increase the photosensitizing activities of #Drug2.,1,DDI type 75 | |
| 20,#Drug1 may increase the QTc-prolonging activities of #Drug2.,2,DDI type 76 | |
| 40,#Drug1 may increase the respiratory depressant activities of #Drug2.,2,DDI type 77 | |
| 32,#Drug1 may increase the sedative activities of #Drug2.,1,DDI type 78 | |
| 64,#Drug1 may increase the serotonergic activities of #Drug2.,2,DDI type 79 | |
| 23,#Drug1 may increase the stimulatory activities of #Drug2.,2,DDI type 80 | |
| 85,#Drug1 may increase the tachycardic activities of #Drug2.,1,DDI type 81 | |
| 81,#Drug1 may increase the thrombogenic activities of #Drug2.,2,DDI type 82 | |
| 59,#Drug1 may increase the ulcerogenic activities of #Drug2.,1,DDI type 83 | |
| 19,#Drug1 may increase the vasoconstricting activities of #Drug2.,2,DDI type 84 | |
| 38,#Drug1 may increase the vasodilatory activities of #Drug2.,2,DDI type 85 | |
| 84,#Drug1 may increase the vasopressor activities of #Drug2.,1,DDI type 86 |